ArticleWorld journal of surgical oncology2025
Cross-cohort integrative multi-omics analysis of cancer essential gene ATP6V0B to dissect functional characteristics and clinical implications in breast cancer.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundBreast cancer remains a leading cause of cancer-related mortality in women, with recurrence, metastasis, and therapeutic resistance limiting outcomes. The role of vacuolar ATPase subunit ATP6V0B in breast cancer pathogenesis and immune regulation is poorly understood.
methodsWe integrated CRISPR screening, machine learning (LASSO/Random Forest), and multi-omics data (> 10,000 samples) to identify ATP6V0B as a cancer essential gene. Single-cell transcriptomics and ligand-receptor network analysis dissected its TME regulatory role. Prognostic modeling (Cox regression/nomogram) was validated across cohorts.
resultsATP6V0B was overexpressed in tumors, correlating with larger size, lymph node metastasis, aggressive subtypes (basal-like/HER2-enriched), and poor prognosis (OS/RFS/DMFS, p < 0.001). ATP6V0B+ tumor subsets are associated with immunosuppression via VEGFA-VEGFR2/THBS1-CD47, correlating with MDSC infiltration and immunotherapy resistance. A nomogram integrating ATP6V0B-related signature, stage, and age improved prognostic accuracy (1/3/5-year OS AUC 0.78/0.74/0.72).
conclusionATP6V0B is a prognostic biomarker and therapeutic target in breast cancer, driving immune evasion. The nomogram enables individualized prognostic assessment, supporting precision oncology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.